<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:chebi fb="0" ids="50864">Glitazones</z:chebi> are powerful insulin sensitisers prescribed for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Their use is, however, associated with fluid retention and an increased risk of <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We previously demonstrated that <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> increases proximal <z:chebi fb="199" ids="26708">sodium</z:chebi> reabsorption in healthy volunteers </plain></SENT>
<SENT sid="3" pm="."><plain>This study examines the effects of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> on renal <z:chebi fb="199" ids="26708">sodium</z:chebi> handling in individuals prone to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, i.e. those with <z:mp ids='MP_0002055'>diabetes</z:mp> and/or <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: In this double-blind randomised placebo-controlled four-way crossover study, we examined the effects of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (45 mg daily during 6 weeks) or placebo on renal, systemic and hormonal responses to changes in <z:chebi fb="199" ids="26708">sodium</z:chebi> intake in 16 individuals, eight with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and eight with <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> was associated with a rapid increase in body weight and an increase in diurnal proximal <z:chebi fb="199" ids="26708">sodium</z:chebi> reabsorption, without any change in renal haemodynamics or in the modulation of the renin-angiotensin <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> system to changes in salt intake </plain></SENT>
<SENT sid="6" pm="."><plain>A compensatory increase in brain natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> levels was observed </plain></SENT>
<SENT sid="7" pm="."><plain>In spite of <z:chebi fb="199" ids="26708">sodium</z:chebi> retention, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> dissociated the blood-pressure response to salt and abolished salt sensitivity in salt-sensitive individuals </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/INTERPRETATION: <z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> increases diurnal proximal <z:chebi fb="199" ids="26708">sodium</z:chebi> retention in diabetic and hypertensive individuals </plain></SENT>
<SENT sid="9" pm="."><plain>These effects cause fluid retention and may contribute to the increased incidence of <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> with <z:chebi fb="0" ids="50864">glitazones</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>TRIAL REGISTRATION: ClinicalTrial.gov NCT01090752 FUNDING: <z:hpo ids='HP_0000822'>Hypertension</z:hpo> Research Foundation Lausanne </plain></SENT>
</text></document>